ArticleCureus2026
Apalutamide-Induced Pneumonitis Presenting as Severe Hypoxemic Respiratory Failure in Metastatic Prostate Cancer: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apalutamide is a widely used second-generation androgen receptor inhibitor for the treatment of metastatic castration-sensitive and nonmetastatic castration-resistant prostate cancer. Although generally well tolerated, rare cases of interstitial lung disease and drug-induced pneumonitis have been reported. Early recognition is critical because of the potential for significant morbidity and mortality. We present a case of suspected apalutamide-induced pneumonitis in a 69-year-old man with metastatic prostate cancer who developed progressive shortness of breath, severe hypoxia, and bilateral ground-glass opacities on imaging. Extensive evaluation excluded infectious, cardiac, and autoimmune etiologies. The patient demonstrated marked clinical and radiographic improvement following the discontinuation of apalutamide and corticosteroid therapy. This case highlights the importance of maintaining a high index of suspicion for drug-induced pulmonary toxicity in patients receiving apalutamide. Prompt diagnosis and early initiation of corticosteroids may significantly improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.